Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.
Locatelli GA, Campiani G, Cancio R, Morelli E, Ramunno A, Gemma S, Hübscher U, Spadari S, Maga G.
Locatelli GA, et al. Among authors: maga g.
Antimicrob Agents Chemother. 2004 May;48(5):1570-80. doi: 10.1128/AAC.48.5.1570-1580.2004.
Antimicrob Agents Chemother. 2004.
PMID: 15105107
Free PMC article.
We have previously described a novel class of nonnucleoside reverse transcriptase (RT) inhibitors, the pyrrolobenzoxazepinone (PBO) and the pyridopyrrolooxazepinone (PPO) derivatives, which were effective inhibitors of human immunodeficiency virus type 1 (HIV-1) RT, either wild t …
We have previously described a novel class of nonnucleoside reverse transcriptase (RT) inhibitors, the pyrrolobenzoxazepinone (PBO) and the …